Leadership

Cornerstone’s experienced management team has a long and successful track record of discovering and developing novel therapeutics and of leading successful entrepreneurial life sciences ventures.  In addition, Cornerstone’s team has operating and leadership experience in all core aspects of building a successful biotechnology company focused on cancer metabolism.  These areas of leadership include the basic science of cancer metabolism, drug discovery, drug development, business development and finance.  Most importantly, Cornerstone’s management brings a deep passion for discovering and developing more effective therapies for treating cancer.

howard

Howard S. Jonas
Chairman of the Board
  • Founder and chairman of IDT Telecommunication Company, Genie Energy, Ltd., IDW Media Holdings, Inc., Net2phone
  • Founder of Straight Path Communication, chairman of Zedge, founder and former board member of Starz Entertainment
Learn More

david a polinsky

David A. Polinsky, Esq.
President and General Counsel/Cofounder
  • Responsible for the management of all legal matters affecting or involving Cornerstone, including corporate governance, financings, intellectual property, licensing, and mergers and acquisitions
Learn More

robert shorr

Robert Shorr,
PhD, DIC

CSO/Cofounder

  • 40 year track record in drug discovery from concept through approval, market launch
  • Enzon Pharma, responsible for co-development of PEG INTRON A with Schering Plough

Learn More


sanjeev luther

Sanjeev Luther
COO

  • More than 25+ years’ experience in healthcare industry including specialty pharmaceuticals, biopharmaceuticals in strategy, business development, alliance, and commercialization

Learn More


Brian Mullaney

Brian Mullaney,
MD, PhD

Chief Medical Officer

  • 20 years’ experience in developing precision medicine, especially in the field of oncology
  • Previously held leadership positions at Novartis, Eli Lilly and Bristol-Myers Squibb

Learn More


paul bingham

Paul Bingham, PhD
VP, Research

  • Co-discoverer of first AEMD compounds
  • Faculty member, Stony Brook Univ.; PhD, Harvard University

Learn More


Timothy Pardee

Timothy S. Pardee,
MD, PhD

Chief Oncologist

  • Played a lead role in the development of the novel metabolism-targeting agent CPI-613.

Learn More


Akiva Mintz

Akiva Mintz,
MD, PhD

Research Director

  • Physician-scientist with 20 years of experience performing impactful translational cancer research and early-stage drug development.

Learn More


                                              
IDT Telecommunication Company